Wedbush Has Positive Outlook for RARE FY2027 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush upped their FY2027 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn $1.05 per share for the year, up from their prior forecast of $1.04. Wedbush currently has a “Neutral” rating and a $48.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.

RARE has been the topic of several other reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Piper Sandler raised their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. JPMorgan Chase & Co. lowered their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. TD Cowen lifted their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $44.05 on Friday. Ultragenyx Pharmaceutical has a one year low of $37.02 and a one year high of $60.37. The stock has a market cap of $4.07 billion, a PE ratio of -6.81 and a beta of 0.58. The stock has a 50-day moving average of $44.56 and a two-hundred day moving average of $49.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same period last year, the business posted ($2.23) earnings per share. The firm’s revenue was up 42.3% compared to the same quarter last year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the transaction, the chief executive officer now owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in RARE. Millennium Management LLC grew its position in Ultragenyx Pharmaceutical by 103.8% during the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares in the last quarter. Alkeon Capital Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 34.3% during the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after acquiring an additional 769,884 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of Ultragenyx Pharmaceutical by 123.4% in the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock worth $54,872,000 after acquiring an additional 545,600 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $17,468,000. Finally, Ikarian Capital LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $9,943,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.